| (Values in U.S. Thousands) | Sep, 2024 | Sep, 2023 | Sep, 2022 | Sep, 2021 | Sep, 2020 |
| Sales | 126,080 | 132,580 | 99,950 | 105,140 | 94,860 |
| Sales Growth | -4.90% | +32.65% | -4.94% | +10.84% | -5.22% |
| Net Income | -11,540 | -1,540 | -27,270 | 4,240 | 1,120 |
| Net Income Growth | -649.35% | +94.35% | -743.16% | +278.57% | -85.24% |
Surmodics Inc (SRDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Surmodics is a leading provider of medical device and In Vitro Diagnostics (IVD) technologies to the healthcare industry. It reports through two divisions: Medical Devices & IVD.'The Medical Devices segment comprises surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices, international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device, with end markets that include coronary, peripheral, neuro-vascular and urology, among others. The IVD segment includes component products and technologies for diagnostic test kits and biomedical research applications, with products that include protein stabilization reagents, substrates, antigens and surface coatings.
Fiscal Year End Date: 09/30